Last Updated: 08/08/2022
VivAction, Finding better tools for the diagnosis and treatment of P. vivax malaria
Objectives
To support critical activities to catalyze adoption and eventual scale-up of vivax tools by delivering on three interlinked outcomes to achieve major impact on P. vivax malaria:
- availability of an expanded set of tools for comprehensive P. vivax case management including pediatric radical cure treatment (PQ & TQ);
- revision of WHO and national guidelines based on feasibility evidence; and
- adoption of new tools towards comprehensive P. vivax case management
Accounting for between 5.9 and 7.1 million estimated clinical cases every year, P. vivaxis the most common type of malaria outside of sub-Saharan Africa. It presents a major challenge to achieving global malaria targets because of the difficulties in eliminating hypnozoites, a form of the parasite that remains in a person’s liver even after successful blood-stage treatment, leading to malaria relapses and contributing significantly to transmission.
Tackling P. vivax, by treating both the blood- and liver-stages of infection – known as radical cure – is essential to achieve the WHO 2030 targets of reducing global malaria case incidence by at least 90% and eliminating malaria transmission in 35 countries; as well as target 3.3 of the Sustainable Development Goals: end the epidemics of AIDS, TB and malaria by 2030.
Under this new Partnership for Vivax Elimination (PAVE), Medicines for Malaria Venture (MMV), PATH, Menzies School of Health Research, and Burnet Institute will work with in-country partners to conduct feasibility studies looking at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the health care system in endemic countries
May 2021 — Feb 2025
$25M
Related Resources
